Drug reference

Canakinumab

Monoclonal Antibody · Immunosuppressant

Also known as Ilaris

Monoclonal AntibodyImmunosuppressant

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

Manufacturer advises avoid unless potential benefit outweighs risk.

FDA category + note

Top interactionssee all 12 →

AdalimumabSevereDatabaseDDInter
BaricitinibSevereDatabaseDDInter
CertolizumabSevereDatabaseDDInter
CladribineSevereDatabaseDDInter

Mechanism

Canakinumab is a recombinant human monoclonal antibody that selectively inhibits interleukin-1 beta (IL-1β) by binding to it. This action prevents IL-1β from binding to its receptors, thereby inhibiting its pro-inflammatory effects. Elevated IL-1 levels are associated with active inflammation.

Indications

Gouty arthritis [in patients whose condition has not responded adequately to treatment with NSAIDs or colchicine, or in those with contra-indications or intolerances to them, and in whom repeated courses of corticosteroids are inappropriate]Cryopyrin-associated periodic syndromes (specialist use only)Tumour necrosis factor receptor associated periodic syndrome (specialist use only)Hyperimmunoglobulin D syndrome (specialist use only)Familial Mediterranean fever (specialist use only)Still’s disease (specialist use only)cryopyrin-associated periodic syndromesactive systemic juvenile idiopathic arthritischronic obstructive pulmonary disease (being evaluated)

Dosing

Adult: For Gouty arthritis: 150 mg for 1 dose by subcutaneous injection; may be repeated after at least 12 weeks if symptoms recur. Administer to the upper thigh, abdomen, upper arm or buttocks. For Cryopyrin-associated periodic syndromes (body-weight 41 kg and above): 150 mg every 8 weeks by subcutaneous injection; additional doses may be considered if clinical response not achieved within 7 days.…
Renal adjustment: No dose adjustment required.